Maria L. Iacovino

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 27, 2026

Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients.

Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 17, 2025

Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients.

Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients.

Journal: Journal of cancer policy

Published: May 22, 2025

Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.

Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.

Journal: Journal of translational medicine

Published: February 11, 2025

Press releases of industry-sponsored clinical trials in oncology: Characteristics, timing and financial impact.

Press releases of industry-sponsored clinical trials in oncology: Characteristics, timing and financial impact.

Journal: Journal of cancer policy

Published: February 06, 2025

Withdrawal notice to .

Withdrawal notice to .

Journal: The Lancet regional health. Europe

Published: October 24, 2024

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Journal: The Lancet regional health. Europe

Published: July 22, 2024

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Journal: The Lancet regional health. Europe

Published: May 30, 2024

Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.

Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.

Journal: The Lancet regional health. Europe

Published: January 30, 2024

Circulating vitamin D level before initiating chemotherapy impacts on the time-to-outcome in metastatic colorectal cancer patients: systematic review and meta-analysis.

Circulating vitamin D level before initiating chemotherapy impacts on the time-to-outcome in metastatic colorectal cancer patients: systematic review and meta-analysis.

Journal: Journal of translational medicine

Published: September 30, 2023

Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.

Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.

Journal: International journal of molecular sciences

Published: December 22, 2021

Immunotherapy for head and neck cancer: Present and future.

Immunotherapy for head and neck cancer: Present and future.

Journal: Critical reviews in oncology/hematology

Published: April 27, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026